BioXcel Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BTAI, updated each market day.
BTAI AI Sentiment
AI predicts BioXcel Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: June 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About BioXcel Therapeutics, Inc. Common Stock
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Sector
Exchange
Market Cap
$38,597,006
Cap Tier
Employees
29
Headquarters
NEW HAVEN, CT
Listed Since
March 8, 2018
BTAI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BTAI Volatility
BioXcel Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
